---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-009829"
form_type: "8-K"
ticker: "MREO"
cik: "0001719714"
company_name: "Mereo BioPharma Group plc"
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:54:12.814550+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Mereo BioPharma reports setrusumab Phase 3 miss; extends cash runway to mid-2027

## Summary
- Cash and equivalents $41M as of Dec 31, 2025; reduced pre-commercial spend extends runway to mid-2027.
- Setrusumab Phase 3 Orbit/Cosmic missed primary fracture-rate endpoints; BMD secondary endpoint met (p<0.001).
- Alvelestat Phase 3 plan: single 220-patient trial over 18 months; partnering discussions ongoing.
- Vantictumab out-licensed to ashibio for ADO2; Phase 2 expected 2H 2026; Mereo retains EU rights.
- No approved OI therapies in US/EU except Italy's neridronate; high unmet need remains.

## SEC filing metadata
- accession: 0001193125-26-009829
- form_type: 8-K
- ticker: MREO
- cik: 0001719714
- company_name: Mereo BioPharma Group plc
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719714/000119312526009829/0001193125-26-009829-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719714/000119312526009829/mreo-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-009829
- JSON: https://secwatch.observer/filing/0001193125-26-009829.json
- Plain text: https://secwatch.observer/filing/0001193125-26-009829.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.